ESPE2015

1 October 2015
07:30-19:00		Registration
08:00-11:00		Working Group WG1 - ESPE Bone and Growth Plate (BGP) Working Group Chair(s):Ola Nilsson (Stockholm, Sweden) & Gabriele Häusler (Vienna, Austria) Hall 3
08:00	WG1.1	Short stature: blame the chondrocyte Jeffery Baron (Bethesda, USA)
08:30	WG1.2	The role of NFkB in growth plate chondrogenesis Francesco Luca (Philadelphia, USA)
09:00		Coffee Break
09:30	WG1.3	Genetics of juvenile osteoporosis Outimaija Mäkitie (Helsinki, Finland)
10:00	WG1.4	Bone tissue characteristics in pediatric bone disease Nadja Fratzl-Zelman (Vienna, Austria)
10:30	WG1.5	Fracture prevention in cystic fibrosis Maria Bianchi (Milan, Italy)
08:00-11:00		Working Group WG2 - ESPE Working Group on Diabetes Technology and Therapeutics Chair(s):Moshe Phillip (Petah Tikva, Israel) & Tadej Battelino (Ljubljana, Slovenia) Hall 1
08:00		Introductions Moshe Phillip (Israel)
08:05	WG2.1	New technologies in treating patients with type 2 diabetes Paolo Pozzilli (Rome, Italy)
08:30	WG2.2	Debate: Are genetic tests necessary before starting a treatment of a patient with Neonatal Diabetes? Michel Polak (Paris, France)
08:30	WG2.3	Debate: Are genetic tests necessary before starting a treatment of a patient with Neonatal Diabetes? Moshe Phillip (Israel)
09:10		Coffee Break
09:30	WG2.4	Debate: Blood glucose monitoring - which is the better: continuous real-time or episodic real-time on demand? Revital Nimri (Petah Tikva, Israel)
09:31	WG2.5	Debate: Blood glucose monitoring - which is the better: continuous real-time or episodic real-time on demand? Olga Kordonouri, MD ()
10:10	WG2.6	Type 2 diabetes mellitus in adolescence Thomas Reinehr (University of Witten/Herdecke, Datteln, Germany)
10:35	WG2.7	The rationale and potential role of surgery in the treatment of adolescent diabetes Thomas Inge (Cincinnati, USA)
08:00-11:00		Working Group WG3 - ESPE Working Group on Disorders of Sex Development (DSD) Chair(s):Paul Martin Holterhus (Kiel, Germany) & Anna Nordenström (Stockholm, Sweden) Hall 2
08:00		Welcome Anna Nordenström (Karolinska University Hospital, Stockholm, Sweden)
08:00	WG3.1	Maternal, placental and fetal steroid hormone synthesis: the key facts for understanding DSDs Christa Flück (Bern, Switzerland)
08:30	WG3.2	DSD in Indonesia: the course of psychological development in late identified patients Arianne Dessens (Rotterdam, The Netherlands)
09:00		Coffee Break
09:30	WG3.3	Work accomplished by the European Reference Network
10:15	WG3.4	I-DSD and I-CAH registry update Faisal Ahmed (Glasgow, United Kingdom)
10:30	WG3.5	EU-Study: dsd-LIFE Birgit Köhler (Berlin, Germany)
10:45		DSD Open Business Meeting Anna Nordenström (Karolinska University Hospital, Stockholm, Sweden)
08:00-11:00		Working Group WG4 - ESPE Obesity Working Group (OWG) Chair(s):Jesús Argente (Madrid, Spain) & Bessie Spiliotis (Patras, Greece) Hall 7
08:00	WG4.1	The endocrine role of brown adipose tissue Francesc Villarroya (Spain)
08:40	WG4.2	A monomeric peptide triagonist for the treatment of obesity and diabetes Christoffer Clemmensen (Munich, Germany)
09:20		Coffee Break
09:40	WG4.3	Genetic approach to understanding severe early-onset childhood obesity Luis Pérez-Jurado (Barcelona, Spain)
10:20	WG4.4	Understanding gene-diet interactions as an approach for the treatment of obesity José Ordovás (Boston, USA)
08:00-11:00		Working Group WG5 - ESPE Working Group on Paediatric and Adolescent Gynaecology (PAG) Chair(s):Marco Cappa (Rome, Italy) & Charles Sultan (Montpellier, France) Hall 4
08:00	WG5.1	Impact of malignancies and their treatment on reproductive function in girls Charles Sklar (New York, USA)
08:30	WG5.2	Preservation of fertility pre-therapy Michaël Grynberg (Bondy, France)
09:00	WG5.3	Restoration of fertility in cancer adolescents after chemotherapy Jacques Donnez (Brussels, Belgium)
09:30		Coffee Break
10:00	WG5.4	Diagnosis and management of endometriosis in adolescence Patrick Puttemans (Leuven, Belgium)
10:30	WG5.5	Uterus transplantation with live births – an update Mats Brännström (Gothenburg, Sweden)
08:00-11:00		Working Group WG6 - ESPE Working Group on Turner Syndrome (TS) Chair(s):Siska Verlinde & Malcolm Donaldson / Ewa Malecka-Tendera & Jenielle van Alfen Hall 5
08:00		Welcome Berit Kriström (Umea, Sweden)
08:05	WG6.1	Incidental prenatal diagnosis of Turner Syndrome, perspectives of parents and professionals Jacqueline Pieters (Leiderdorp, The Netherlands)
08:45	WG6.2	The challenges of prenatal diagnosis: the experience of a supportive group for parents of children with TS Maura Foresti (Bologna, Italy)
09:15		Coffee Break
09:30	WG6.3	Impact of age at start and GH dose for height gain and age at adult height in TS girls Berit Kriström (Umea, Sweden)
10:00	WG6.4	Management of middle ear and hearing problems in Turner's syndrome - how can we do better? Malcolm Donaldson (Glasgow, United Kingdom)
10:30	WG6.5	Report on the progress and difficulties on transdermal Estradiol supplementation in Europe Theo Sas (Rotterdam, The Netherlands)
11:15-11:30		Opening Ceremony Hall 1
11:30-12:00		Plenary 1 Chair(s):Ragnar Hanas (Uddevalla, Sweden) & Luis Castaño (Bilbao, Spain) Joint ESPE-ISPAD Session Hall 1
11:30	PL1	Genetic and environmental determinants of type 1 diabetes Marian Rewers (Colorado, USA)
12:00-12:30		Plenary 2 Chair(s):Ragnar Hanas (Uddevalla, Sweden) & Luis Castaño (Bilbao, Spain) Joint ESPE-ISPAD Session Hall 1
12:00	PL2	New advances in monogenetic diabetes Andrew Hattersley (Exeter, UK)
12:30-14:00		Lunch, Visit to Posters and Exhibition
12:30-13:30		P1 Mini-Poster Presentations
		Adrenal: P1-1 to P1-11
		Bone: P1-12 to P1-22
		Diabetes: P1-23 to P1-33
		Growth Hormone: P1-78 to P1-88
		Perinatal: P1-100 to P1-110
12:45-13:45		Industry Sponsored Satellite Symposium 1
14:00-15:30		Symposium 1 - The effect of hormonal abnormalities on Neurocognition Chair(s):Jesús Argente (Madrid, Spain) & George Chrousos (Athens, Greece) Hall 3
14:00	S1.1	The effect of thyroid hormones on the brain Joanne Rovet (Toronto, Canada)
14:30	S1.2	The effect of diabetes mellitus on neurocognition Fergus Cameron (The Royal Children's Hospital Melbourne, Victoria, Australia)
15:00	S1.3	The effects of growth hormone and anabolic androgenic steroids on the brain Alfhild Grönbladh (Uppsala, Sweden)
14:00-15:30		Symposium 2 - Adipose tissue: Beyond classical concepts Chair(s):Martin Wabistch (Ulm, Germany) & Antje Körner (Leipzig, Germany) Hall 5
14:00	S2.1	Brown adipose tissue and its therapeutic potential Sven Enerbäck (Gothenburg, Sweden)
14:30	S2.2	Is brown adipose tissue relevant to paediatrics? Vicente Gilsanz (Los Angeles, USA)
15:00	S2.3	Lipodystrophies: new approaches for diagnostic workup and treatment Corinne Vigouroux (Paris, France)
14:00-15:30		Symposium 3 - Disorders of sex development: An update Chair(s):Nils Krone (Sheffield, UK) & Olaf Hiort (Luebeck, Germany) Hall 2
14:00	S3.1	Novel genes identified in male and female sex development Ken McElreavey (Paris, France)
14:30	S3.2	Decision Making in DSD: Development of a Decision Support Tool. David Sandberg (Michigan, USA)
15:00	S3.3	Genetic and enviromental disruption of testicular function Olle Söder (Stockholm, Sweden)
14:00-15:30		Symposium 4 - Management of thyroid disorders: Current best practice Chair(s):Jan-Maarten Wit (Leiden, The Netherlands) & Annette Greuters-Kieslich (Berlin, Germany) Hall 1
14:00	S4.1	Screening, diagnosis and management of congenital hypothyroidism Heiko Krude (Berlin, Germany)
14:30	S4.2	Management of hyperthyroidism in children Scott Rivkees (Gainesville, USA)
15:00	S4.3	Genetics of congenital hypothyroidism and associated problems Jose Moreno (Madrid, Spain)
15:30-16:00		Coffee Break
16:00-17:00		Meet the Expert Sessions
	MTE1.1	Management of adrenal tumours Constantine Stratakis (Greece)
	MTE2.1	Translation of diabetes technologies to clinical practice Olga Kordonouri, MD ()
	MTE3.1	Challenges in the management of short stature Jesús Argente (Madrid, Spain)
	MTE4.1	Use of hormone replacement in females with endocrine disorders Sophie Christin-Maitre (Paris, France)
16:00-17:00		Controversies 1: Debate - Is bariatric surgery the management of choice for obese adolescents? Chair(s):Wieland Kiess (Leipzig, Germany) & Bessie Spiliotis (Athens, Greece) Hall 4
		For the Motion Thomas Inge (Cincinnati, USA)
		Against the Motion Thomas Reinehr (University of Witten/Herdecke, Datteln, Germany)
16:00-17:00		Yearbook of Paediatric Endocrinology Chair(s):Franco Chiarelli (Chieti, Italy) Hall 1 Session head(s):
	YB1.1	Obesity and weight regulation Professor Martin Wabitsch (University of Ulm, Germany)
	YB1.2	Type 2 diabetes, metabolic syndrome and lipids Orit Pinhas-Hamiel (Tel Aviv, Israel)
	YB1.3	Type 1 diabetes Wieland Kiess (Hospital for Children and Adolescence, University of Leipzig, Leipzig, Germany)
	YB1.4	Evidence based medicine in pediatric endocrinology Rod Mitchell (The University of Edinburgh , Edinburgh, UK)
	YB1.5	Editor's choice Ken Ong (Cambridge, United Kingdom)
17:15-18:45		Industry Sponsored Satellite Symposium 2 - 4
18:45-		Welcome Reception Exhibition area
2 October 2015
07:30-19:00		Registration
08:00-09:00		Meet the Expert Sessions
	MTE8.1	Looking beyond nutritional rickets: From the foetus to the infant Wolfgang Högler (Linz, Austria)
	MTE5.1	Management of the adolescent with CAH Peter Hindmarsh (London)
	MTE6.1	Management of Prader-Willi syndrome in toddlers Maithé Tauber (Toulouse, France)
	MTE7.1	Management of late-effects in the child/adolescent with cancer Charles Sklar (New York, USA)
09:15-10:15		Free Communications 1 - Adrenal Chair(s):Berenice Mendonca (Sao Paulo, Brazil) & Christa Flück (Bern, Switzerland) Hall 2
09:15	FC1.1	A genomic atlas of human gonad and adrenal development John Achermann (London, United Kingdom)
09:25	FC1.2	Involvement of the Wnt/beta-catenin pathway, SF1, DAX1 and stem/progenitor cell markers in paediatric adrenocortical tumors (ACTs) Marcelo Cavalcanti (San Paolo, Brazil)
09:35	FC1.3	Aldosterone and mineralocorticoid receptor as inducers of immune markers in peripheral blood mononuclear cells: beyond elevating blood pressure Andrea Vecchiola (Santiago, Chile)
09:45	FC1.4	Congenital adrenal hyperplasia due to 21 OH deficiency: final height before and after newborn screening era in Emilia-Romagna region, Italy Bologna, Italy ()
09:55	FC1.5	Atypical presentation of six patients with mutations in the side chain cleavage enzyme CYP11A1 Lou Metherell (Queen Mary University of London, London, UK)
10:05	FC1.6	An update on noninvasive prenatal diagnosis of congenital adrenal hyperplasia using cell-free foetal DNA in maternal plasma Maria New (New York, USA)
09:15-10:15		Free Communications 2 - Bone & Mineral Metabolism Chair(s):Dov Tosiano (Israel) & Serap Turan (Istanbul, Turkey) Hall 3
09:15	FC2.1	Whole exome sequencing analysis of patients with autosomal recessive hypophophatemic rickets identified mutations in DMP1, ENPP1 and SLC34A3 Dong Li (Philadelphia, USA)
09:25	FC2.2	Identification of mutations in TBX1 and AIRE in isolated hypoparathyroidism patients Dong Li (Philadelphia, USA)
09:35	FC2.3	High success of a next generation sequencing panel for the molecular diagnosis of rare skeletal dysplasias Karen Heath (Madrid, Spain)
09:45	FC2.4	Asfotase alfa: sustained efficacy and tolerability in children with hypophosphatasia treated for 5 years Katherine Madson (St. Louis, USA)
09:55	FC2.5	Methyl donor deficiency impairs differentiation of pre-osteoblasts through disruption of functional interaction between peroxisome proliferator-activated receptor-gamma coactivator-1 alpha and vitamin D receptor Eva Feigerlova (Nancy, France)
10:05	FC2.6	A contextual feature-based recognition approach to quantify trabecular microstructure using 1.5T axial-MRI: an innovative methodology Paul Dimitri (Sheffield Children’s NHS Foundation Trust, Sheffield, UK)
09:15-10:15		Free Communications 3 - Diabetes Chair(s):Alfonso Lechuga (Spain) & Silva Arslanian Hall 4
09:15	FC3.1	RNA-based MAFA over-expression is sufficient to drive human pancreatic duct-derived cells toward a -cell-like phenotype Elisa Corritore (Brussels, Belgium)
09:25	FC3.2	Experience with molecular diagnosis in 48 cases of neonatal diabetes mellitus using targeted next-generation sequencing Yulia Tikhonvich (Moscow, Russia)
09:35	FC3.3	Clinical characteristics and molecular genetic analysis of 6 patients with pancreas aplasia and neonatal diabetes: predominance of PTF1A-enhancer mutations Klemens Raile (Berlin, Germany)
09:45	FC3.4	Wolfram syndrome: natural history and genotype-phenotype correlation based on EURO-WABB Registry show gender differences in disease severity Renuka Dias (Birmingham Women’s and Children’s NHS Foundation Trust , Birmingham, UK)
09:55	FC3.5	C-peptide levels and glycemic control in children, adolescents and young adults with type 1 diabetes (TID) Maria Xatzipsalti (Athens, Greece)
10:05	FC3.6	First report of nationwide incidence and prevalence of type 1 diabetes among children in Turkey Ediz Yesilkaya (Ankara, Turkey)
09:15-10:15		Free Communications 4 - Growth Chair(s):Jovanna Dahlgren & Gary Butler (London, UK) Hall 5
09:15	FC4.1	Heterozygous dominant negative STAT5B variants associated with short stature and GH insensitivity Evelien Pease-Gevers (London, UK)
09:25	FC4.2	A recurrent homozygous NDUFB3 mutation, p.Trp22Arg causes a short stature disorder and mitochondrial protein complex I deficiency with a variable metabolic phenotype Philip Murray (Manchester, UK)
09:35	FC4.3	An updated and final analysis of a randomised placebo-controlled trial of the effect of oxandrolone and timing of pubertal induction on final height in Turner syndrome Emma-Jane Gault (Glasgow, UK)
09:45	FC4.4	Modulation of GH-1 splicing as potential strategy to rescue growth hormone deficiency type II Maria Mileta (Bern, Switzerland)
09:55	FC4.5	Stunted growth after inhaled corticosteroid use during the first 24 months of life Antti Saari (Kuopio, Finland)
10:05	FC4.6	Positive association between height and cancer in the Swedish population Emelie Benyi (Stockholm, Sweden)
09:15-10:15		Free Communications 5 - Endocrine Oncology / Turner Syndrome Chair(s):(Mohammed Maghnie (Genoa, Italy) & Cristina Azcona (Pamplona, Spain) Hall 7
09:15	FC5.1	Resveratrol potentiates growth inhibitory effects of rapamycin in PTEN-deficient lipoma cells by suppressing p70S6 kinase activity Jenny Leipert (Leipzig, Germany)
09:25	FC5.2	MEN1 syndrome because of combined germline and somatic mosaicism, with important consequences for relatives Marlies Kempers (Nijmegen, The Netherlands)
09:35	FC5.3	Screening in children with Succinate dehydrogenase B (SDHB) mutations: a single centre’s family clinic experience Lucy Shapiro (London, UK)
09:45	FC5.4	X chromosome gene dosage and the risk of developing congenital and acquired traits in Turner syndrome: a cross-sectional database analysis of the French national rare disease network Delphine Zenaty (Paris, France)
09:55	FC5.5	Hereditary Turner syndrome 46,X,rec(X)inv(p21q28) in six women and four generations: estimation of skeletal effects of growth hormone treatment Judith Stoklasova (Prague, Czech Republic)
10:05	FC5.6	Anti-Müllerian hormone levels in patients with Turner syndrome: relation to karyotype, pubertal development and growth hormone therapy Rasha Hamza (Cairo, Egypt)
09:15-10:15		Yearbook of Paediatric Endocrinology Chair(s):Primus Mullis (Bern, Switzerland) Hall 1
	YB2.1	Pituitary and neuroendocrinology Nicolas de Roux (Paris, France)
	YB2.2	Reproductive Endocrinology Olle Söder (Stockholm, Sweden)
	YB2.3	Antenatal and Neonatal Endocrinology Khalid Hussain (Sidra Medicine, Doha, Qatar)
	YB2.4	Growth and growth factors Stefano Cianfarani (University of Rome Tor Vergata, Rome, Italy)
	YB2.5	Type 1 diabetes Wieland Kiess (Hospital for Children and Adolescence, University of Leipzig, Leipzig, Germany)
09:15-10:15		New Perspectives Session 1 Chair(s):Cheri Deal (Montreal, Canada) Hall 6
	NP1.1	Pancreatic development using zebrafish as a model Didier Stainier (Bad Nauheim, Germany)
	NP1.2	Optogenetic control of neuroendocrine hormone secretion Allan Herbison (University of Cambridge, Cambridge, UK)
10:45-11:15		Plenary 3 Chair(s):Jean-Claude Carel (Paris, France) & Mehul Dattani (London, UK) Hall 1
10:45	PL3	New advances in human evolution from the analysis of ancient genomes Carles Lalueza-Fox (Barcelona, Spain)
11:15-12:15		ESPE Awards and Activities 1 Chair(s):Anita Hokken-Koelega (Rotterdam, The Netherlands) & Jan Lebl (Prague, Czech Republic) Hall 1
		ESPE Young Investigator Award 1 & 2 – sponsored by Pfizer
		ESPE Schools – sponsored by ESPE (Diabetes, Obesity and Metabolism School), Ferring Pharmaceuticals (Summer, Winter and Caucasus & Central Asia Schools), Novo Nordisk Gulf (ASPED-ESPE School), and Pfizer (Maghreb School)
		ESPE Fellowships and Sabbatical Leave Programme – sponsored by Novo Nordisk A/S (Research Fellowship), Merck Serono SA (Clinical Fellowship) and Eli Lilly and Company (Sabbatical Leave Programme)
		ESPE Hormone Research in Paediatrics Prizes – sponsored by Karger A.G.
		ESPE International Award – sponsored by Pfizer
		ESPE Research Award – sponsored by Pfizer
12:15-12:45		Plenary 4 Chair(s):Jean-Claude Carel (Paris, France) & Mehul Dattani (London, UK) Hall 1
12:15	PL4	Genomic diversity in present day humans: Evolutionary aspects Alan Templeton (St Louis, USA)
12:45-14:30		Lunch, Visit to the Posters and Exhibition
12:45-13:45		P1 Mini Poster Presentations
		Diabetes: P1-34 to P1-44
		DSD: P1-56 to P1-66
		Growth: P1-89 to P1-99
		Turner & Puberty: P1-133 to P1-143
		Misc: P1-144 to P1-154
13:15-14:15		Industry Sponsored Satellite Symposium 5
14:15-16:15		ESPE Working Group for Paediatic Endocrine Nurse Specialists and Allied Health Professionals (PENSWG) Chair(s):Kate Davies (London, UK) & Christine Derycke (Brussels, Belgium) Hall 6
14:15	WG7.1	Nurse run short stature screening clinic Wendy Schwarz (Canada)
14:35	WG7.2	Quality management initiatives in pediatric endocrinology: Selected case study and clinical initiatives Irena Hozjan (Canada)
14:55		Q & A from the first two speakers
15:10	WG7.3	Getting a patient off of medication due to coaching and care. A case report Viviane Crommert (The Netherlands)
15:20	WG7.4	Long-term outcome of a male preschooler treated for central precocious puberty Jan Foote (Iowa, USA)
15:30	WG7.5	Pan-Canadian experience of pediatric endocrine nurses assisting youth through gender transition Nicole Kirouac (Manitoba, Canada)
15:40		Q & A from the above case study speakers
15:55	WG7.6	Sharing Resources: Hypothyroidism Christine Davies (UK)
14:30-16:00		Symposium 5 - Developmental Programming: Novel concepts Chair(s):Stefano Cianfarani (Rome, Italy) & Ruben Diaz (Spain) Hall 5
14:30	S5.1	Developmental programming of reproductive function: Early life nutritional impacts Deborah Sloboda (Hamilton, Canada)
15:00	S5.2	Transgenerational developmental programming of endocrine disease Susan Ozanne (Cambridge, UK)
15:30	S5.3	Intergenerational programming of metabolic disease Mary Patti (Boston, USA)
14:30-16:00		Symposium 6 - Type 2 Diabetes & Obesity Chair(s):Tadej Battelino (Ljubljana, Slovenia) & Jan Lebl (Prague, Czech Republic) Hall 1
14:30	S6.1	Can genotype be used to tailor treatment of obesity? José Ordovás (Boston, USA)
15:00	S6.2	New and old drugs for treatment of type 2 diabetes in children David Dunger (Cambridge)
15:30	S6.3	From obesity to type 2 diabetes Silva Arslanian (Pittsburgh, USA)
14:30-16:00		Symposium 7 - Hypogonadotropic hypogonadism: diagnostic and therapeutic approach Chair(s):Nicholas de Roux (Paris, France) & Maria Clemente Hall 2
14:30	S7.1	Early therapeutic approach to the male patient with HH Claire Bouvattier (Paris, France)
15:00	S7.2	Pubertal induction and fertility prospects in the male Nelly Pitteloud (Lausanne, Switzerland)
15:30	S7.3	Modeling GnRH deficiency with the use of human pluripotent cells Taneli Raivio (Helsinki, Finland)
14:30-15:30		Controversies 2: Debate - Should pre-natal treatment for CAH be offered? Chair(s):Peter Hindmarsh (London, UK) Hall 4
		For the Motion Véronique Tardy-Guidollet (Lyon, France)
		Against the Motion Svetlana Lajic (Stockholm, Sweden)
14:30-16:00		Special Symposium - Recommendations for surveillance for thyroid cancer in survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group Chair(s):Hanneke van Santen Hall 3
14:30	SS1.1	Introduction of the IGHG-thyroid group, its members and aims Dr endocrinologist, (The Netherlands)
14:35	SS1.2	Methodology of the IGHG recommendations Drs recommendation, (The Netherlands)
14:45	SS1.3	Which cancer survivors are at risk for thyroid cancer; summary of the evidence Dr endocrinologist, (Tennessee, USA)
15:00	SS1.4	Is detection of thyroid cancer in an early stage beneficial ? Drs Clement, (The Netherlands)
15:10	SS1.5	Which evaluation modality is most sensitive and specific for detecting thyroid carcinoma in an early stage; summary of the evidence and decision tree analysis. Dr Goldfarb (California, USA)
15:20	SS1.6	Pro-Con debate - Arguments in favour of screening survivors at risk with palpation of the neck Dr Frey, (Vienna, Austria)
15:35	SS1.6	Pro - Con Debate: Arguments in favour of screening survivors at risk with thyroid ultrasound Scott Rivkees (Gainesville, USA)
15:50	SS1.7	Further steps of the IGHG group; forming a decision aid. HM Santen (The Netherlands)
14:30-16:00		Special Symposium - Opportunities and challenges in accessing essential medications in low and middle income countries Chair(s):Reiko Horikawa (Japan) Hall 7
14:30	SS2.1	Facilitating Access to Essential Medicines: role of WHO Suzanne Hill ((Geneva, Switzerland))
15:00	SS2.2	Bringing essential medicines into low income countries: opportunities and challenges for the pharmaceutical Avinash Shejale ((Mumbai, India))
15:30	SS2.3	A model for the sustainable access to medicines for the management of congenital adrenal hyperplasia (CAH) in a low income setting Jean-Pierre Chanoine (Vancouver, Canada)
16:15-17:45		ESPE Annual Business Meeting ESPE Members Only
18:00-19:30		Industry Sponsored Satellite Symposium 6 - 8
3 October 2015
07:30-18:30		Registration
08:00-09:00		Meet the Expert Sessions
	MTE1.2	Management of adrenal tumours Constantine Stratakis (Greece)
	MTE3.2	Challenges in the management of short stature Jesús Argente (Madrid, Spain)
	MTE4.2	Use of hormone replacement in females with endocrine disorders Sophie Christin-Maitre (Paris, France)
	MTE7.2	Management of late-effects in the child/adolescent with cancer Charles Sklar (New York, USA)
	MTE2.2	Translation of diabetes technologies to clinical practice Olga Kordonouri, MD ()
09:15-10:15		New Perspectives Session 2 Chair(s):Ze'ev Hochberg (Haifa, Israel) & Gabriele Haeusler Hall 7
	NP2.1	Engineering cartilage Marcel Karperien (Enschede, The Netherlands)
	NP2.2	Astrocytes and neuroendocrine control Julie Chowen (Madrid, Spain)
09:15-10:15		New Technologies Session Chair(s):Ken Ong (Cambridge, UK) & Laura De Graff (The Netherlands) Hall 6
	NT1	New technologies in imaging Chris Clark (London, UK)
	NT2	Next Generation Sequencing: Implementing the 100,000 genome project for treatment of NHS patients Tim Hubbard (London, UK)
09:15-10:15		Free Communications 6 - Gonads & DSD Chair(s):Tsutomu Ogata (Japan) & John Achermann (London, UK) Hall 1
09:15	FC6.1	Correlation of AR expression and AR transcriptional activity in cultured human genital fibroblasts PD Nadine Hornig, PhD (Kiel, Germany)
09:25	FC6.2	A role for DMRT1 in human primary sex-determination Sandra Rojo (Minneapolis, USA)
09:35	FC6.3	Establishing the role of the steroid backdoor pathway for androgen biosynthesis in the human ovary Nesa May (Bern, Switzerland)
09:45	FC6.4	Severe 46, XY disorder of sex development (DSD) due to CBX2 isoform 2 mutation is distinct from CBX2.1 deficiency and is likely due to EMX2 dysregulation in the human developing gonad Wassim Eid (Fribourg, Switzerland)
09:55	FC6.5	Characterisation of mutations in the androgen receptor (AR) identified in 38 Brazilian families with complete or partial androgen insensitivity syndrome (AIS) Rafael Batista (Sao Paulo, Brazil)
10:05	FC6.6	Frequency of gonadal tumour in complete androgen insensitivity syndrome (CAIS): a retrospective case-series analysis Saduf Chaudhry (Cambridge, UK)
09:15-10:15		Free Communications 7 - Growth promoting therapies Chair(s):Gerhard Binder (Tuebingen, Germany) & Alexander Augusto de Lima Jorge (São Paulo, Brazil) Hall 2
09:15	FC7.1	Safety and effectiveness of Increlex® therapy in children with Laron syndrome and enrolled in the European Increlex® Growth Forum Database (EU-IGFD) in Europe Peter Bang (Linköping, Sweden)
09:25	FC7.2	Topicon™ ThermoMatrix™-mediated passive transdermal delivery of insulin-like growth factor 1 (IGF-1) Across EpidermFT™ full-thickness human skin equivalent (HSE): towards an extended-wear IGF-1 Patch Stephen Hsu (Florida, USA)
09:35	FC7.3	IGF-I levels, complex formation and igf-bioactivity in growth hormone treated children with Prader-Willi syndrome Nienke Bakker (Rotterdam, The Netherlands)
09:45	FC7.4	A novel reversible albumin-binding growth hormone derivative possesses a promising once-weekly treatment profile in children with growth hormone deficiency Tadej Battelino (University of Ljublijana, Ljubljana, Slovenia)
09:55	FC7.5	12 month safety and efficacy of a weekly long-acting growth hormone (GH, MOD-4023) compared to daily recombinant human GH (rh)GH) therapy in pre-pubertal growth hormone deficient children; Phase 2 study – Study CP-4-004 Summary Ron Rosenfeld (Oregon, USA)
10:05	FC7.6	Pharmacokinetic (PK) and pharmacodynamics (PD) modelling of MOD 4023 (a long-acting human growth hormone (hGH)) in growth hormone deficient (GHD) children Gili Hart (Nes Ziona, Israel)
09:15-10:15		Free Communications 8 - Obesity Basic Chair(s):Jean-Pierre Chanoine & Carlo Acerini (Cambridge, UK) Hall 3
09:15	FC8.1	DLK1 expression in adipose tissue following fetal growth restriction: relation to visceral fat expansion and catch-up growth in Wistar rats Gemma Carreras-Badosa (Girona, Spain)
09:25	FC8.2	Apoptosis inhibitor of macrophages (AIM): an anti-inflammatory adipocyte factor in mild adolescent obesity? Alexia Karvela (Patras, Greece)
09:35	FC8.3	Testing the Appetite Suppressing Effects of Vitamin B12 Conjugates of Peptide YY Christian Roth (Seattle, USA)
09:45	FC8.4	Severe early-onset obesity caused by bioinactive leptin due to a N103K mutation Professor Martin Wabitsch (University of Ulm, Germany)
09:55	FC8.5	Adipocytokines in placenta and cord blood in relation to maternal obesity, and foetal and postnatal growth of the child Maria Lodefalk (Örebro, Sweden)
10:05	FC8.6	Metabolic effects of ADP355, protein-based adiponectin receptor agonist, on mice with high-fat diet induced fatty liver disease Eun Lee (Inchon, Republic of Korea)
09:15-10:15		Free Communications 9 - Beta cell disorders Chair(s):John Gregory (Cardiff, UK) & Ritika Kapoor Hall 4
09:15	FC9.1	Islet δ-cells contribute to the pathobiology of atypical congenital hyperinsulinism Bing Han (Manchester, UK)
09:25	FC9.2	A novel source of mesenchymal stem cells lines from the human neonatal pancreas of patients with congenital hyperinsulinism in infancy Sophie Kellaway (Manchester, UK)
09:35	FC9.3	Failure to terminate cell proliferation contributes to the pathobiology of congenital hyperinsulinism in infancy Bing Han (Manchester, UK)
09:45	FC9.4	Novel molecular mechanisms of congenital hyperinsulinism due to autosomal dominant mutations in ABCC8 Azizun Nessa (London, UK)
09:55	FC9.5	The use of glucagon for management of severe-persistent hypoglycaemia in patients with congenital hyperinsulinism Klaus Mohnike (Germany)
10:05	FC9.6	Pharmacokinetics (PK) of a new suspension of glibenclamide for use in young patients and infants with neonatal diabetes Jacques Beltrand (Paris, France))
10:45-11:45		ESPE Awards and Activities 2 Chair(s):Laura Audí (Barcelona, Spain) & Lars Sävendahl (Stockholm, Sweden) Hall 1
		Henning Andersen Prizes – sponsored by Novo Nordisk A/S
		ESPE Research Unit – sponsored by ESPE and Sandoz International GmbH
		IFCAH-ESPE award – supported by The International Fund for Research on Congenital Adrenal Hyperplasia
		ESPE Outstanding Clinician Award – sponsored by Pfizer
		ESPE International Outstanding Clinician Award – sponsored by Pfizer
		Andrea Prader Prize – sponsored by Pfizer
11:45-12:15		Plenary 5 Chair(s):Lourdes Ibanez Hall 1
11:45	PL5	Ontogeny of FGF21 in the human: Implications for metabolic health Francesc Villarroya (Spain)
12:30-13:30		Yearbook of Paediatric Endocrinology Chair(s):Juliane Léger (Paris, France) Hall 1
	YB3.1	Adrenals Evangelia Charmandari (Athens, Greece)
	YB3.2	THyroid Gabor Szinnai (Basel, Switzerland)
	YB3.3	Bone, Growth plate and mineral metabolism Outi Mäkitie (Helsinki, Finland)
	YB3.4	Oncology and chronic disease Carla Bizzarri (Rome, Italy)
	YB3.5	The Year in Science and Medicine Ze'ev Hochberg (Haifa, Isreal))
12:30-13:30		Free Communications 10 - Perinatal endocrinology Chair(s):Rod Mitchell (Edinburgh, UK) & Irène Netchine (Paris, France) Hall 2
12:30	FC10.1	Effect of sonic hedgehog signalling on regulation the expression of 11β-HSD2 in the placenta Chao Zou (Hangzhou, China)
12:40	FC10.2	The altered circulating miRNA profile in maternal obesity associate with pre- and post-natal growth Judit Bassols (Salt, Spain)
12:50	FC10.3	Circulating miRNA expression profile in pregestational and gestational obesity Judit Bassols (Salt, Spain)
13:00	FC10.4	Effect of P450 oxidoreductase variants on metabolism by cytochrome P450 proteins Shaheena Parween (Bern, Switzerland)
13:10	FC10.5	Lack of association between transient hypothyroxinaemia of prematurity and neurodevelopmental and behavioral outcomes in young adulthood Josephina Hollanders (Amsterdam, The Netherlands)
13:20	FC10.6	Heterozygous hypomorphic mutation in the INS gene could cause transient neonatal diabetes in extremely low birth weight neonates Tohru Yorifuji (Osaka, Japan)
12:30-13:30		Free Communications 11 - Neuroendocrinology Chair(s):Ivo Arnhold (Sao Paulo, Brazil) & Malcolm Donaldson (Glasgow, Scotland) Hall 3
12:30	FC11.1	Mutations in BRAF are associated with septo-optic dysplasia and cardiofaciocutaneous syndrome Rachel Besser (Oxford University Hospitals NHS Foundation Trust, Oxford, UK)
12:40	FC11.2	Functional characterisation of a POU1F1 mutation unexpectedly associated with isolated growth hormone deficiency (IGHD): a novel aetiology of IGHD Marie-Laure Sobrier (Paris, France)
12:50	FC11.3	Next generation sequencing: towards a new clinical frontier in the diagnosis and management of pituitary tumours Mark McCabe (New South Wales, Australia)
13:00	FC11.4	Idiopathic multiple pituitary hormone deficiency (IMPHD): radiological and perinatal factors Nimasari Ginige (Birmingham, UK)
13:10	FC11.5	Endocrinopathy after intracranial germ cell tumours (IGCT) is disease not radiation- related: two decades of surveillance in a large tertiary paediatric cohort Eftychia Dimitrakopoulou (London, UK)
13:20	FC11.6	Long-term outcome of patients treated for paediatric Cushing's disease Galina Yordanova (London, UK)
12:30-13:30		Free Communications 12 - Obesity clinical Chair(s):Juan-Pedro Lopez-Siguero & Veronica Mericq Hall 4
12:30	FC12.1	Evaluation of cardiovascular risk in childhood: data from a survey of dyslipidaemic children Patrizia Bruzzi (Modena, Italy)
12:40	FC12.2	Soluble CD163, a circulating marker of macrophage activation, associates with a less favourable metabolic profile in children Gemma Carreras-Baosa (Girona, Spain)
12:50	FC12.3	Re-classification of childhood obesity by steroid metabolomic disease signature Aneta Gawlik (Katowice, Poland)
13:00	FC12.4	RM-493, a melanocortin-4 receptor (MC4R) agonist, is being therapeutically evaluated in patients with deficiencies in the Leptin – Proopiomelanocortin (POMC) – MC4R hypothalamic pathway, including Prader-Willi syndrome (PWS) Peter Kühnen (Berlin, Germany)
13:10	FC12.5	Link between body mass index and insulin requirement in children and young people with type 1 diabetes mellitus Swathi Upadrasta (Ormskirk, UK)
13:20	FC12.6	Initial experience with endoscopically placed duodenal-jejunal bypass liner (Endobarrier®) in morbidly obese adolescents
12:30-13:30		Free Communications 13 - Thyroid Chair(s):Michel Polak (Paris, France) Hall 5
12:30	FC13.1	Gain of function STAT3 mutation in a boy with early onset autoimmune diabetes and thyroid disease, prenatal and postnatal growth impairment and lymphoproliferation Hana Sediva (Prague, Czech Republic)
12:40	FC13.2	Analysis of chosen polymorphisms rs2476601 A/G - PTPN22, rs1990760 C/T - IFIH1, rs179247 A/G - TSHR in pathogenesis of autoimmune thyroid diseases in children Aleksandra Goralczyk (Bialystok, Poland)
12:50	FC13.3	Targeted next-generation sequencing demonstrates high frequency of ‘dyshormonogenesis genes’ mutations in severe congenital hypothyroidism Nina Makretskaya (Moscow, Russia)
13:00	FC13.4	Effects of initial levothyroxine dose on growth and neurodevelopmental outcomes during the first year of life in children with congenital hypothyroidism Andrea Esposito (Naples, Italy)
13:10	FC13.5	Effect of two years of treatment with levothyroxine on cardiovascular risk factors in children with mild idiopathic subclinical hypothyroidism Manuela Cerbone (London, UK)
13:20	FC13.6	TRIAC treatment of allan-herndon-dudley syndrome (AHDS) due to defects in thyroid hormone transporter MCT8 A Iglesias (Madrid, Spain)
12:30-13:30		Free Communications 14 - Puberty Chair(s):Dolores Rodriquez-Amao & Abdullah Bereket Hall 7
12:30	FC14.1	KLB, encoding the co-receptor for FGF21, is mutated in congenital hypogonadotropic hypogonadism Cheng Xu (Lausanne, Switzerland)
12:40	FC14.2	A mutation in HS6ST1 causes self-limited delayed puberty Sasha Howard (Queen Mary University of London and Barts Health NHS Trust, London, UK)
12:50	FC14.3	The new syndrome of hypogonadotropic hypogonadism, arrythmogenic right ventricular dysplasia, facial dysmorphism and absence of corpus callosum is associated to TAX1 binding protein 3 gene mutation Eli Hershkovitz (Beer Sheva, Israel)
13:00	FC14.4	Genetic variation of AMH signaling affects AMH and inhibin B levels in healthy peripubertal girls Casper Hagen (Copenhagen, Denmark)
13:10	FC14.5	Polybrominated diphenyl ethers (PBDEs) and timing of puberty in girls Annalisa Deodati (Rome, Italy)
13:20	FC14.6	An evaluation of glandular breast tissue development and volume by MRI in 121 healthy peripubertal girls Louise Fugl (Copenhagen, Denmark)
12:30-13:30		Free Communications 15 - Late Breaking Chair(s):Carlos Longui & Olle Söder (Stockholm, Sweden) Hall 6
12:30	FC-LB-1	RNA Sequencing Reveals The Pathways Perturbed by Redox Imbalance in Nicotinamide Nucleotide Transhydrogenase null mice. Eirini Meimaridou (London)
12:40	FC-LB-2	Loss of Neuronal Dmxl2 impairs the maturation and the activation of GnRH neurons: a new mechanism of GnRH deficiency. Carole Harbulot (Paris, France)
12:50	FC-LB-3	Pharmacokinetic and Pharmacodynamic Studies of Topicon™-Mediated Patch Delivery of Insulin Glargine in a Streptozotocin-Induced Hairless Rat Model Stephen Hsu (Florida, USA)
13:00	FC-LB-4	Long-term cognitive effects of antenatal dexamethasone treatment in Swedish adolescents with and without CAH Lena Wallensteen (Stockholm, Sweden)
13:10	FC-LB-5	Paternally inherited IGF2 mutation results in intrauterine and postnatal growth retardation Gerhard Binder (Tübingen, Germany)
13:20	FC-LB-6	PROP1 mutations cause hypopituitarism by disrupting the transition of pituitary stem cells to differentiation Maria Millan (Michigan, USA)
13:30-		Lunch, Visit to the Posters and Exhibition
13:30-14:30		P1 Mini Poster Presentations
		Diabetes: P1-45 to P1-55
		Fat: P1-67 to P1-77
		Puberty: P1-111 to P1-121
		Thyroid: P1-122 to P1-132
		Misc: P1-155 to P1-165
13:45-15:15		ESPE Education and Training Hall 6
14:00-15:00		Industry Sponsored Satellite Symposium 9
15:30-17:00		Symposium 8 - Diabetes & Obesity as infectious diseases Chair(s):Maria Chueca (Spain) & Zdenek Sumnik (Prague, Czech Republic) Hall 1
15:30	S8.1	Disentangling disease and drug signatures in the human gut microbiome Oluf Pedersen (Copenhagen, Denmark)
16:00	S8.2	The role of the gut microbiome for immunity and metabolism Rémy Burcelin (Toulouse, France)
16:30	S8.3	Gut microbiome modulates the risk for islet autoimmunity Ondrej Cinek (Prague, Czech Republic)
15:30-17:00		Symposium 9 - Childhood Craniopharyngioma: Recent Advances Chair(s):Lidia Castro (Santiago de Compostela, Spain) & Helen Spoudeas (London, UK) Hall 2
15:30	S9.1	Outcomes in patients with childhood craniopharyngioma Hermann Mueller (Ludwig Maximilian University of Munich, Munich, Germany)
16:00	S9.2	Surgical approach to craniopharyngioma Michael Buchfelder (Erlangen, Germany)
16:30	S9.3	Potential novel therapies for craniopharyngioma: Insights from a mouse model Carles Gaston-Massuet (University of London , London, UK)
15:30-17:00		Symposium 10 - Growth plate & nutrition Chair(s):Faisal Ahmed (Glasgow, UK) & Agnes Linglart (Paris, France) Hall 4
15:30	S10.1	Molecular mechanisms of growth plate adaptation during undernutrition Francesco Luca (Philadelphia, USA)
16:00	S10.2	Molecular response of the growth plate to inflammatory cytokines Lars Sävendahl (Stockholm, Sweden)
16:30	S10.3	Bone health in chronic disease Jarod Wong (Glasgow, UK)
15:30-16:30		Meet the Expert Sessions
	MTE5.2	Management of the adolescent with CAH Peter Hindmarsh (London)
	MTE6.2	Management of Prader-Willi syndrome in toddlers Maithé Tauber (Toulouse, France)
	MTE8.2	Looking beyond nutritional rickets: From the foetus to the infant Wolfgang Högler (Linz, Austria)
17:00-17:30		Coffee Break
17:30-17:45		President Poster Award Chair(s):Laura Audí (Barcelona, Spain) Hall 1
17:45-18:15		Plenary 6 Chair(s):Peter Clayton (Manchester, UK) & Mitch Geffner (Los Angeles, UK) Hall 1
17:45	PL6	The complex relationship between the GH/IGF axis and aging and longevity – the interface with diet and mitochondrial peptides Pinchas Cohen (Los Angeles, USA)
18:15-18:30		Closing Ceremony Chair(s):Laura Audí (Barcelona, Spain), Peter Clayton (Manchester, UK) & Jean-Claude Carel (Paris, France) Hall 1
19:00-23:59		ESPE Evening

ESPE2015

1 October 2015

2 October 2015

3 October 2015